Lymphocyte Apoptosis and Its Association with the Inflammatory Markers and Disease Severity in Juvenile-onset Systemic Lupus Erythematosus Patients

Overview

Journal Pediatr Rheumatol Online J

Publisher Biomed Central

Specialty Pediatrics

Date 2024 Jan 19

PMID 38243322

Authors

Eman Eissa

Rania Kandil

Dalia Dorgham

Raghda Ghorab

Naglaa Kholoussi

Affiliations

Soon will be listed here.

Abstract

Background: The defective clearance of apoptotic bodies in juvenile-onset systemic lupus erythematosus (jSLE) potentially leads to the persistence of autoreactive lymphocytes and the perpetuation of the autoimmune response. These factors contribute to the disturbance in lymphocyte apoptosis and show potential as key determinants in the clinical course and severity of jSLE. This study evaluates the role of peripheral blood (PB) lymphocyte apoptosis in prognosis of jSLE and as a predictor for disease activity.

Methods: The study involved 100 jSLE patients and 50 healthy controls. Flow cytometry was used to analyze percentages of lymphocyte apoptosis in PB of all study participants. Plasma levels of pro-inflammatory cytokines were determined using ELISA.

Results: Our results showed that percentages of lymphocyte apoptosis in PB of jSLE patients are significantly higher than those of healthy controls. These percentages are significantly positively associated with disease activity of patients (SLEDAI-2 K). Furthermore, plasma cytokine levels (IL-17, IFN-γ and TNF-α) are significantly elevated in jSLE patients compared to their levels in healthy controls. Also, there are weak significant positive correlations between percentages of PB lymphocyte apoptosis and each of IL-17 and IFN-γ plasma levels in jSLE patients. Moreover, PB lymphocyte apoptosis percentages among jSLE patients are higher in the presence of some clinical and laboratory features than those in their absence.

Conclusion: Peripheral apoptotic lymphocytes could contribute to the prognosis of jSLE and could be used as a predictor for disease activity in jSLE patients.

Citing Articles

Association between platelet-to-lymphocyte ratio and immune checkpoint inhibitor-induced thyroid dysfunction.

Wang A, Huang H, Chen Y, Zhao Z, Cong L, Li M Endocrine. 2025; .

PMID: 39838195 DOI: 10.1007/s12020-025-04164-4.

References

Tang Y, Tao H, Gong Y, Chen F, Li C, Yang X . Changes of Serum IL-6, IL-17, and Complements in Systemic Lupus Erythematosus Patients. J Interferon Cytokine Res. 2019; 39(7):410-415. DOI: 10.1089/jir.2018.0169. View

Robert M, Miossec P . Interleukin-17 and lupus: enough to be a target? For which patients?. Lupus. 2019; 29(1):6-14. DOI: 10.1177/0961203319891243. View

Ren Y, Savill J . Apoptosis: the importance of being eaten. Cell Death Differ. 1999; 5(7):563-8. DOI: 10.1038/sj.cdd.4400407. View

De George D, Ge T, Krishnamurthy B, Kay T, Thomas H . Inflammation versus regulation: how interferon-gamma contributes to type 1 diabetes pathogenesis. Front Cell Dev Biol. 2023; 11:1205590. PMC: 10244651. DOI: 10.3389/fcell.2023.1205590. View

Bengtsson A, Sturfelt G, Gullstrand B, Truedsson L . Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus - an additional mechanism to increased autoantigen load?. Clin Exp Immunol. 2004; 135(3):535-43. PMC: 1808958. DOI: 10.1111/j.1365-2249.2003.02386.x. View

Koga T, Ichinose K, Kawakami A, Tsokos G . Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus. Front Immunol. 2021; 11:624971. PMC: 7882681. DOI: 10.3389/fimmu.2020.624971. View

Hammad A, Osman E, Mosaad Y, Wahba M . Serum interleukin-17 in Egyptian children with systemic lupus erythematosus: is it related to pulmonary affection?. Lupus. 2016; 26(4):388-395. DOI: 10.1177/0961203316665709. View

Hedrich C, Smith E, Beresford M . Juvenile-onset systemic lupus erythematosus (jSLE) - Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2018; 31(4):488-504. DOI: 10.1016/j.berh.2018.02.001. View

Alduraibi F, Sullivan K, Chatham W, Hsu H, Mountz J . Interrelation of T cell cytokines and autoantibodies in systemic lupus erythematosus: A cross-sectional study. Clin Immunol. 2023; 247:109239. PMC: 10118038. DOI: 10.1016/j.clim.2023.109239. View

10.

Su Y, Cheng T, Chen C, Chiu W, Hsu C, Chang W . The association among leukocyte apoptosis, autoantibodies and disease severity in systemic lupus erythematosus. J Transl Med. 2013; 11:261. PMC: 3853096. DOI: 10.1186/1479-5876-11-261. View

11.

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

12.

Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan K, George S . Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006; 35(3-4):148-53. DOI: 10.1016/j.cyto.2006.07.023. View

13.

Tahghighi F, Ziaee V, Moradinejad M, Rezaei A, Harsini S, Soltani S . Tumor necrosis factor-alpha single nucleotide polymorphisms in juvenile systemic lupus erythematosus. Hum Immunol. 2015; 76(8):533-6. DOI: 10.1016/j.humimm.2015.06.011. View

14.

Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T . Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987; 70(3):562-9. PMC: 1542177. View

15.

Navratil J, Liu C, Ahearn J . Apoptosis and autoimmunity. Immunol Res. 2007; 36(1-3):3-12. DOI: 10.1385/IR:36:1:3. View

16.

Smith E, Lythgoe H, Midgley A, Beresford M, Hedrich C . Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019; 209:108274. DOI: 10.1016/j.clim.2019.108274. View

17.

Theofilopoulos A, Koundouris S, Kono D, Lawson B . The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 2001; 3(3):136-41. PMC: 128889. DOI: 10.1186/ar290. View

18.

Taylor P, Carugati A, Fadok V, Cook H, Andrews M, Carroll M . A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med. 2000; 192(3):359-66. PMC: 2193213. DOI: 10.1084/jem.192.3.359. View

19.

Yang L, Anderson D, Baecher-Allan C, Hastings W, Bettelli E, Oukka M . IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008; 454(7202):350-2. PMC: 2760130. DOI: 10.1038/nature07021. View

20.

Volpe E, Servant N, Zollinger R, Bogiatzi S, Hupe P, Barillot E . A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008; 9(6):650-7. DOI: 10.1038/ni.1613. View